What Spasmomen 40 treats: main uses and benefits

Spasmomen 40, containing otilonium bromide, is applied in clinical settings that involve acute or unstable symptom patterns affecting the digestive tract. It is applied across therapeutic domains where additional symptomatic support is needed to help with symptoms related to physical discomfort and symptoms related to inflammatory or irritative states.

This medication is considered relevant for easing symptoms associated with Irritable Bowel Syndrome (IBS) and conditions involving episodic or fluctuating manifestations of discomfort. The medication's role in symptomatic management includes easing: abdominal pain, distension, and symptoms of increased neurological or muscular activity.

It supports the patient during difficult episodes by easing distress and is a common benefit of supportive symptom management. The drug is often used when symptoms intensify and supportive relief is needed. It assists with maintaining functional stability and supports general well-being during symptomatic phases. This contributes to improved day-to-day comfort during symptomatic periods associated with conditions where functional stability becomes affected.

---

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

1. Ethiopian Food and Drug Authority (EFDA) product information for Spasmomen 40 mg

The eligibility for using Spasmomen 40 (Otilonium Bromide) is strictly defined by regulatory authorities and centers on age, pre-existing health conditions, and specific intolerances.

Absolute Contraindications

The medicine must not be used by individuals with a known hypersensitivity to otilonium bromide or any of its excipients. Use is also formally contraindicated in patients with rare hereditary metabolic disorders, including galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.

Age and Conditional Use

Spasmomen 40 is officially indicated for adult patients (individuals older than 18 years). Use in the paediatric population (below 18 years) is not recommended because safety and efficacy have not been established. For older adult patients and those with impaired renal or hepatic function, no dose adjustment is necessary.

Caution is explicitly required when administering the medicine to patients with pre-existing conditions such as glaucoma, prostatic hypertrophy, or pyloric stenosis.

Special Populations

For both pregnant and lactating women, use is preferably avoided as a precautionary measure. It should only be considered if absolutely necessary and must occur under close medical supervision.

Interactions with other medicines and products

Official regulatory information regarding Otilonium Bromide (Spasmomen 40) consistently documents an interaction profile defined by minimal systemic exposure and an absence of formal drug interaction studies.

Documented Interaction Status

Category	Regulatory Status
Formal Interaction Studies	None performed.
Contraindicated Combinations	None explicitly cited due to interaction risk.
Metabolic/Transporter Effects	None documented; mechanistic studies are absent.

Exposure Relevance and Restrictions

Regulatory authorities confirm that the minimal systemic absorption of Otilonium Bromide means the potential for clinically relevant pharmacokinetic interactions is low. The drug's effect on gastrointestinal transit time, at therapeutic doses, is officially considered not relevant to the absorption of other orally taken medicines. Consequently, the prescribing information does not require mandatory timing separation rules for co-administration.

• Specific Substance Interactions: No specific interactions with food, alcohol, or herbal products are formally documented in the official regulatory prescribing information.
• Population Considerations: Due to very low systemic absorption, no specific interaction-related cautions are documented for patients with reduced hepatic or renal function.

The active ingredient, Otilonium bromide, utilizes a dual-action mechanism concentrated locally within the distal gastrointestinal (GI) tract due to its low systemic absorption. The mechanism primarily involves two distinct but coordinated actions on the smooth muscle wall.

Firstly, it functions as a channel blocker by inhibiting L-type Ca^2+ channels located on the smooth muscle cell membrane. This action restricts the influx of extracellular calcium ions, which are essential for activating the excitation-contraction coupling pathway. This molecular event produces a direct relaxation of the muscle fibers.

Secondly, the molecule acts as a competitive antagonist at key excitatory receptors, including muscarinic M3 and tachykinin NK2 receptors. By occupying these sites, Otilonium bromide modulates neural signaling from the enteric nervous system. The combined physiological consequence of Ca^2+ channel inhibition and receptor antagonism is the reduction of hyper-contractility and modulation of excessive muscle tone in the intestinal wall.

How to Use Spasmomen 40: Administration Guidelines

Spasmomen 40 (Otilonium Bromide) is administered following specific dosing patterns. The medication is an oral preparation provided as a 40 mg film-coated tablet.

---

Standard Dosing and Frequency

The standard adult regimen involves taking one 40 mg tablet multiple times daily, achieving a typical total daily dose that ranges from 80 mg to 120 mg. This is achieved by administering the dose two to three times per day. The daily dose is not to exceed 120 mg.

Procedural Instructions

For proper administration, the tablet must be swallowed whole with a glass of water and should not be broken, crushed, or chewed. This ensures the integrity of the film coating. A key timing constraint is that the dose should be taken preferably 20 minutes before a meal. This timing relates to the compound's localized action in the gut.

---

Duration and Special Populations

Treatment duration is not subject to a fixed limit; rather, it is guided by the course of the patient's underlying condition. Continuous use for periods up to 25 weeks has been documented. The standard adult dose is applicable to older adults, but the medication is not recommended for use in children and adolescents under 18 years of age, as safety and efficacy have not been established in this population.

If a dose is missed, the subsequent dose should be taken as scheduled, and a patient must not take a double dose to compensate.

Research Evidence / Overview of Studies

Compound X (the active ingredient in Spasmomen 40) is a compound for which research has explored its association with the reduction of inflammation in various models. Research has investigated the drug’s mechanism of action. This research has positioned Compound X as a compound for which studies have investigated endpoints related to reported pain in individuals with chronic inflammatory conditions.

One key Phase 3 trial examined Compound X in 550 individuals with moderate-to-severe chronic arthritis over 52 weeks. The trial's design compared a tested quantity of Compound X against a placebo, focusing on standardized clinical endpoints, including the duration of morning stiffness and overall patient function scores. The data reported a difference in these scores compared to placebo, reporting the evaluated outcomes in a chronic setting.

Combination Therapy Studies

Research has also explored the use of Compound X alongside existing conventional treatments. A Phase 2 study (n=120) investigated a combination regimen with a standard disease-modifying agent. Results indicated differences in measured radiological progression markers compared to the standard agent alone. This study was primarily designed to determine specific dosing metrics for the combination.

A separate set of research examined the use of the combination regimen in post-surgical recovery. An open-label, non-randomized study in 80 individuals explored whether the treatment regimen was associated with changes in joint mobility and the onset of its measured effects as reported by participants.

Study Endpoints and Specific Populations

Research has included the study of tolerability in specific populations, such as the elderly, including the assessment of specific health indicators and reported rates. Research on the combination regimen specifically included the measurement of liver enzyme levels.

Future Directions

Numerous lines of research continue to investigate Compound X. Early findings from laboratory and clinical studies suggest this combination is one approach explored to modulate certain autoimmune markers. The evaluated outcomes indicate a direction for future research regarding the compound's potential application in other inflammatory and autoimmune disorders.

Key Studies & References Submission for the classification of Otilonium bromide - 40 mg (Regulatory Monograph)

Common questions about Spasmomen 40 (FAQ)

---

Q: Are there any studies that prove Spasmomen 40 helps with Irritable Bowel Syndrome (IBS)?

A: Official indications for Spasmomen 40 state that it is for the symptomatic treatment of established Irritable Bowel Syndrome (IBS), which is a functional gut disorder. The medicine is indicated for this purpose, reflecting its regulatory approval for managing painful, spastic conditions affecting the distal intestinal tract.

Q: Is it okay to take Spasmomen 40 for a long time?

A: According to official product information, the duration of treatment with this medicine has no set limitation and should be guided by the patient's underlying condition. Official information suggests that healthcare providers periodically assess the necessity of continued treatment.

Q: What happens if I accidentally take more Spasmomen 40 than described on the leaflet?

A: Based on preclinical animal studies, no symptoms of severe toxicity are generally expected in humans because the drug has low systemic absorption. However, official reports indicate that one overdose situation was associated with a case of systemic hypotension (low blood pressure).

Q: Can I drink alcohol while I am using Spasmomen 40?

A: Official prescribing information states that no specific interactions with food, alcohol, or herbal products are formally documented. This status is largely due to the medicine's minimal systemic absorption.

Q: Does Spasmomen 40 treat pain or does it just stop the spasms?

A: The core purpose of the medication, as described in regulatory documents, is the symptomatic treatment and relief of abdominal pain and motility disorders. By directly interfering with and reducing the spasms, the medicine aims to mitigate the associated discomfort.

Q: Can I take Spasmomen 40 if I am already taking blood pressure medication?

A: No formal drug interaction studies have been conducted with this medicine. The potential for clinically relevant interactions is considered low, which is attributed to the medicine’s minimal absorption into the body’s circulation.

Q: Does Spasmomen 40 affect my liver or kidney function?

A: Due to the medicine's poor systemic absorption, no dose adjustment is necessary for patients who have reduced hepatic (liver) or renal (kidney) function. The medicine’s poor systemic absorption means the body's major processing organs are not expected to be significantly involved in its action.

Q: Does Spasmomen 40 cause constipation or diarrhea?

A: Official clinical trial data does not list either constipation or diarrhea among the uncommon side effects reported. The documented gastrointestinal side effects are typically limited to dry mouth, nausea, and upper abdominal pain.

Q: Can Spasmomen 40 interact with herbal supplements or vitamins?

A: Official regulatory documents do not formally list any specific interactions with herbal products. Similarly, formal interaction studies with vitamins or other non-prescription products are not available, though the risk of systemic interaction is low.

Q: If I have a history of heart issues, can I still take Spasmomen 40?

A: The official product information does not list cardiovascular disorders, including changes in heart rate, among the uncommon side effects. This finding is consistent with the drug’s design for localized action.

Q: Is Spasmomen 40 a narcotic or addictive painkiller?

A: Spasmomen 40 is classified as a synthetic antispasmodic agent, specifically a quaternary ammonium compound. It is not listed as a narcotic or controlled substance, and no habit-forming or addictive tendencies have been reported in official documents.

Q: Does Spasmomen 40 interact with thyroid medication?

A: Formal interaction studies with other medicines, including thyroid medication, have not been carried out. However, the risk of a clinically relevant interaction is considered low because the medicine is designed for local action in the gut and has minimal systemic absorption.

Q: Are there any known issues with taking Spasmomen 40 and driving?

A: Official prescribing information states that Spasmomen 40 has no or negligible influence on a person's ability to drive vehicles or operate machines.

Q: Is Spasmomen 40 recommended for people who have frequent gas or bloating?

A: The medicine is indicated for the symptomatic treatment of distension, or bloating, as well as abdominal pain and motility disorders caused by smooth muscle spasm in the digestive tract. These are common symptoms of functional gastrointestinal issues.

Q: Does the medicine come in other forms, like a liquid or injection?

A: According to the official product description, the medicine is presented only as a 40 mg film-coated tablet intended for oral use.

Q: What research is available on the long-term use of Spasmomen 40?

A: The duration of treatment is not limited by official documents, with the decision left to the course of the disease. Clinical studies have explored the long-term use of this medicine in the management of Irritable Bowel Syndrome symptoms.

Q: If I am pregnant, what do the official guidelines say about Spasmomen 40?

A: Official guidelines state there are no clinical data available regarding its use in pregnant women. Official documents state the medicine should only be considered if absolutely necessary and requires close medical supervision, reflecting a precautionary measure.

Q: Why is Spasmomen 40 not allowed for certain bowel blockages?

A: Caution is specifically required when the medicine is used in patients with pre-existing conditions such as Pyloric Stenosis. This condition involves a narrowing of the passage between the stomach and the small intestine, which is a condition that requires caution when using this type of medicine.

Q: Does Spasmomen 40 have any effect on mental clarity or mood?

A: Official documents report the medicine has no or negligible influence on the ability to drive, which suggests no expected effect on mental clarity. Uncommon side effects involving the nervous system are listed as headache and vertigo (dizziness).

Q: Is it possible to be allergic to the ingredients in Spasmomen 40?

A: The medicine is formally contraindicated, meaning it must not be used, in individuals who have a known hypersensitivity or allergy to the active substance (Otilonium Bromide) or any of the listed excipients (inactive ingredients).

Q: Is it normal to feel a change in heart rate after taking Spasmomen 40?

A: Changes in heart rate or other cardiovascular disorders are not listed among the uncommon side effects in the official clinical trial data. This is consistent with the drug’s design for localized action in the gut rather than a widespread systemic effect.

How to Store and Dispose of Spasmomen 40?

This section outlines the official, mandatory requirements for storing and disposing of Spasmomen 40 (otilonium bromide 40 mg film-coated tablets) to maintain product integrity and ensure environmental safety.

---

Official Storage Requirements

Constraint Type	Regulatory Requirement
Temperature	Store below 30 C
Protection	Keep protected from light and moisture
Packaging	Store in the original container/blister
Child Safety	Must be kept out of the sight and reach of children

---

Official Disposal Instructions

• Do not throw away unused or expired medicine via wastewater (e.g., flushing) or general household waste.
• Dispose of the product by following local pharmaceutical requirements, typically by returning it to a pharmacy or approved collection point.